



**Attn: Trading and Market Making/Legal and Compliance/Operations/Systems**  
**UNIFORM PRACTICE ADVISORY (UPC #02-26) 01/06/2026**  
**Arch Therapeutics, Inc. (ARTHQ)**

Notice has been received that the above Company's Second Amended Chapter 11 Plan has become effective on 12/31/2025. Pursuant to the plan the holders of class 5 interest will receive nothing on account of such interests in the debtors. On the effective date, holders of such equity interests shall not receive or retain any property on account of any such interests. All existing equity interests, regardless of class, shall be deemed cancelled, extinguished, and discharged pursuant to the plan, and of no further force or effect, after which zero shares shall be outstanding and no holders of record shall remain. See the Company's Second Amended Chapter 11 Plan for more details.<sup>1</sup>

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations-1-866-776-0800.

---

<sup>1</sup> See e.g., *In re: Arch Therapeutics, Inc., et al., Debtors*. Chapter 11 Case No. 25-40409 (Jointly Administered) Debtor's Second Amended Chapter 11 Plan of Arch Therapeutics, Inc. and Arch Biosurgery Under Chapter 11 of the Bankruptcy Code.